SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Riggs BL,Khosla S,Melton LJ3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002; 23: 279302.
  • 2
    WHO Scientific Group. Prevention and management of osteoporosis. World Health Organization Technical Report Series. 2003; 921: 1192.
  • 3
    Simpson ER,Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res. 2002; 57: 317338.
  • 4
    Geisler J,Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005; 95: 7581.
  • 5
    Breast International Group (BIG) 1–98 Collaborative Group; Thurlimann B,Keshaviah A,Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 27472757. Erratum in:N Engl J Med.2006;354:2200. Wardly, Andrew [corrected to Wardley, Andrew].
  • 6
    Coombes RC,Hall E,Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092. Erratum in:N Engl J Med.2004;351:2461;N Engl J Med.2006;355:1746. van de Velde, Cornelius [added].
  • 7
    Howell A,Cuzick J,Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 8
    Jakesz R,Jonat W,Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455462.
  • 9
    Coleman R, on behalf of theATAC Trialists' Group. Effect of anastrozole on bone mineral density: five-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. Presented at the American Society of Clinical Oncology (ASCO), Atlanta, Georgia, June 2–6, 2006. Abstract 511.
  • 10
    Gnant M,Mlineritsch B,Luschin-Ebengreuth G, et al. Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007; 25: 820828.
  • 11
    Marshall D,Johnell O,Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312: 12541259.
  • 12
    Siris ES,Chen YT,Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004; 164: 11081112.
  • 13
    Johnell O,Kanis JA,Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20: 11851194. Erratum in:J Bone Miner Res.2007;22:774.
  • 14
    Smith MR,Eastham J,Gleason DM,Shasha D,Tchekmedyian S,Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169: 20082012.
  • 15
    Black DM,Delmas PD,Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 18091822.
  • 16
    Brufsky A,Harker WG,Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25: 829836.
  • 17
    Common Toxicity Criteria v3.0 (CTC): National Cancer Institute: Bethesda, MD. Available at: http://ctep.info.nih.gov/reporting/CTC-3.html. Accessed December 3, 2005.
  • 18
    Goss PE,Ingle JN,Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 19
    Eastell R,Hannon R. Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol. 2005; 95: 151154.
  • 20
    Gasser JA,Green JR,Shen V, et al. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone. 2006; 39: 787795.
  • 21
    Van Poznak C,Estilo C. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonates. Oncology (Williston Park). 2006; 20: 10531062.
  • 22
    Hoff AO,Toth B,Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract]. J Clin Oncol. 2006; 24(18 suppl ). Abstract 8528.
  • 23
    NOF National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Available at URL: http//:www.nof/org
  • 24
    Hillner BE,Ingle JN,Chlebowski RT, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21: 40424057. Erratum in:J Clin Oncol.2004;22:1351.
  • 25
    Coleman REBanks LM,Girgis SI, et al. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007; 8: 119127.
  • 26
    Eastell R,Hannon RA,Cuzick J,Dowsett M,Clack G,Adams JE;ATAC Trialists'Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006; 21: 12151223.